Skip navigation


For kidney transplant assessment

Covered by Medicare, Prospera is a transplant rejection assessment test that uses a simple blood draw to evaluate the risk of rejection of a transplanted kidney.

Through the use of advanced cell-free DNA technology, Prospera increases a provider’s ability to identify otherwise undetected rejection that might lead to kidney loss. Catching transplant rejection as soon as possible can help providers develop a treatment plan to best protect the donated kidney.

Prospera offers more precise post-transplant rejection assessment

With a 95% negative predictive value, Prospera misses ~3x fewer rejections than serum creatinine.1 Prospera’s proprietary donor-derived cell-free DNA (dd-cfDNA) technology offers early warning signs of transplant rejection and reduces the likelihood of renal allograft failure with a non-invasive single blood draw.1,2

Comparison of Negative Predictive Values (NPV)
Organ rejection is a problem

Why now?

Organ rejection is a problem

Many kidney transplant failures occur within the first five to ten years7,8 because organ rejection isn’t caught early enough or treated effectively. As a result, the patient needs a new organ and must start the waitlist process again.

Why choose Prospera for rejection assessment?

Built on our deep experience and legacy in cell-free DNA, Prospera is:

Access Prospera through our remote service for routine labs

Find out more about Prospera for Kidney transplant recipients


1Sigdel TK et al. Optimizing detection of kidney transplant injury by assessment of donor-derived cell-free DNA via massively multiplex PCR. J Clin Med. 2019;8(1):19.

2Altuğ Y et al. Analytical validation of a single-nucleotide polymorphism-based donor-derived cell-free DNA assay for detecting rejection in kidney transplant patients. Transplantation, 2019.

3Bloom RD et al. Cell-free DNA and active rejection in kidney allografts. J Am Soc Nephrol. 2017;28(7):2221-2232. doi: 10.1681/ASN.2016091034.

4Grskovic M et al. Validation of a clinical-grade assay to measure donor-derived cell-free DNA in solid organ transplant recipients. J Mol Diagn. 2016;18(6):890-902.

5Organ Donation Statistics. U.S. Department of Health and Human Services. U.S. Government Information on Organ Donation and Transplantation. Published March 31, 2016.

6Kidney Disease Statistics for the United States. National Institute of Diabetes and Digestive and Kidney Diseases. Published Dec. 1, 2016.

7Stegall et al. Through a Glass Darkly: Seeking Clarity in Preventing Late Kidney Transplant Failure, J Am Soc Nephrol. 2015; 26 (1):20-9

8Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal, Am J of Transplantation. 2011; Mar;11(3):450-62.5.

9Bunnapradist, S. Using both fraction and quantity of donor-derived cell-free DNA to detect kidney allograft rejection, J Amer Soc Nephrology 2021, in press

icon-angle icon-bars icon-times